BRIEF-Merck's investigational NNRTI, doravirine, meets primary efficacy endpoint
July 25, 2017 at 08:41 AM EDT
* Merck's investigational NNRTI, doravirine, meets primary efficacy endpoint of non-inferiority to efavirenz, both in combination with other antiretroviral agents, in pivotal phase 3 trial for treatment of hiv-1 infection
